| Title: |
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma |
| Authors: |
Maziarz, Richard T; Bishop, Michael R; Tam, Constantine S; Borchmann, Peter; Worel, Nina; McGuirk, Joseph P; Holte, Harald; Waller, Edmund K; Jaglowski, Samantha; Andreadis, Charalambos; Foley, Stephen Ronan; Westin, Jason R; Fleury, Isabelle; Ho, P Joy; Mielke, Stephan; Teshima, Takanori; Janakiram, Murali; Hsu, Jingmei; Izutsu, Koji; Kersten, Marie José; Ghosh, Monalisa; Wagner-Johnston, Nina; Kato, Koji; Corradini, Paolo; Ma, Wanying; Han, Xia; Nuortti, Marja; Awasthi, Rakesh; Mundt, Kirsten E; Majdan, Marta; Maier, Harald J; Jegerlehner, Andrea; Salles, Gilles; Schuster, Stephen J |
| Contributors: |
R.T. Maziarz; M.R. Bishop; C.S. Tam; P. Borchmann; N. Worel; J.P. Mcguirk; H. Holte; E.K. Waller; S. Jaglowski; C. Andreadi; S.R. Foley; J.R. Westin; I. Fleury; P.J. Ho; S. Mielke; T. Teshima; M. Janakiram; J. Hsu; K. Izutsu; M.J. Kersten; M. Ghosh; N. Wagner-Johnston; K. Kato; P. Corradini; W. Ma; X. Han; M. Nuortti; R. Awasthi; K.E. Mundt; M. Majdan; H.J. Maier; A. Jegerlehner; G. Salle; S.J. Schuster |
| Publisher Information: |
Lippincott Williams and Wilkins |
| Publication Year: |
2026 |
| Collection: |
The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| Subject Terms: |
Settore MEDS-09/B - Malattie del sangue |
| Description: |
We report the 5-year analysis of tisagenlecleucel in 115 infused patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) from the single-arm, open-label, multicenter, global, phase II JULIET trial (ClinicalTrials.gov identifier: NCT02445248), with a median follow-up of 74.3 months. The median duration of response (DOR) was not reached; the 60-month, relapse-free probability was 61% among responders. Higher relapse-free probability (DOR >70%) was observed in females and those with less than two baseline International Prognostic Index risk factors or with baseline stage I/II disease. The estimated probability of progression-free survival at 60 months was 28%. The probability of overall survival (OS) at 60 months was 32% for all infused patients and 56% for those achieving complete or partial response. Baseline characteristics associated with achieving a response at any time after infusion included relapsed versus refractory disease, one versus two or more bridging regimens, lactate dehydrogenase level ≤upper limit of normal (ULN) versus >ULN, and C-reactive protein levels 15 mg/L. Baseline characteristics associated with long-term OS included lactate dehydrogenase ≤ULN and C-reactive protein |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41252666; info:eu-repo/semantics/altIdentifier/wos/WOS:001654884800002; volume:44; issue:2; firstpage:86; lastpage:91; numberofpages:6; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/2434/1226036 |
| DOI: |
10.1200/JCO-25-00507 |
| Availability: |
https://hdl.handle.net/2434/1226036; https://doi.org/10.1200/JCO-25-00507 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.DB270066 |
| Database: |
BASE |